mRNA新冠疫苗接种后心肌炎:一项汇总分析
该汇总分析系统检索多个数据库,纳入报告BNT162b2或mRNA-1273接种后成人心肌炎病例的研究,合并病例报告/系列中的个体数据,并对合并队列与观察性研究进行比例随机效应Meta分析,共纳入39项研究、129例患者。多数病例为年轻男性、发生于第二剂后;心衰体征可预测危重病情(OR 19.22,95%CI 5.57-275.84),完全缓解比例80.5%(95%CI 59.3-92.1),ICU入住比例7.0%(95%CI 3.8-12.9)。作者认为通常病情轻微、病程平稳。
要点
- 多数心肌炎病例发生于年轻男性、第二剂mRNA新冠疫苗后。
- 心衰体征预测后续危重病情(OR 19.22,95%CI 5.57-275.84)。
- 完全缓解80.5%(95%CI 59.3-92.1),ICU入住7.0%(95%CI 3.8-12.9)。
核心结论
- mRNA新冠疫苗接种后心肌炎通常病情轻微,临床病程平稳、症状改善迅速;未来研究需明确其确切发病率、阐明病理生理并确定基于严重程度的最佳管理方案。
研究设计与样本
- 系统检索Medline、Scopus、Web of Science、CENTRAL和Google Scholar(自建库起),纳入报告BNT162b2或mRNA-1273接种后成人心肌炎病例的研究。
- 合并病例报告/系列中的个体参与者数据,并将合并队列与聚合数据的观察性研究进行比例随机效应Meta分析,共纳入39项研究、129例患者。
主要发现
- 多数病例发生于年轻男性、第二剂疫苗后;第一剂后心肌炎与既往新冠感染显著相关(P值:0.025)。
- 最常见心电图表现为ST段抬高,心脏磁共振中晚钆增强均可见。
- 逻辑回归分析显示心衰体征可预测后续危重病情(比值比:19.22,95%置信区间:5.57-275.84)。
- 比例Meta分析显示完全缓解症状者占80.5%(95%CI:59.3-92.1),需入住重症监护室者占7.0%(95%CI:3.8-12.9)。
关键数值与推荐
- 第一剂后心肌炎与既往新冠感染显著相关(P值:0.025)。
- 心衰体征预测危重病情:OR 19.22(95%CI 5.57-275.84)。
- 完全缓解比例80.5%(95%CI 59.3-92.1);ICU入住比例7.0%(95%CI 3.8-12.9)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未来研究需明确其确切发病率、阐明病理生理并确定基于严重程度的最佳管理方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Post-marketing surveillance studies have raised concerns of increased myocarditis rates following coronavirus disease-19 (Covid-19) mRNA vaccines. The present study aims to accumulate the published mRNA Covid-19 vaccine-associated myocarditis cases, describe their clinical characteristics and determine the factors predisposing to critical illness. METHODS: Medline, Scopus, Web of Science, CENTRAL and Google Scholar were systematically searched from inception. Studies reporting adult myocarditis cases following BNT162b2 or mRNA-1273 vaccination were included. Individual participant data coming from case reports/series were pooled. Proportional random-effects meta-analysis was conducted by combining the pooled cohort and observational studies with aggregated data. RESULTS: Overall, 39 studies were included with a total of 129 patients. Most cases occurred in young males after the second vaccine dose. Myocarditis after the first dose was significantly associated with prior Covid-19 (p-value: 0.025). The most common electrocardiographic finding was ST-segment elevation, while late gadolinium enhancement was invariably observed in cardiac magnetic reasoning. Logistic regression analysis demonstrated that signs of heart failure were predictive of subsequent critical illness (Odds ratio: 19.22, 95% confidence intervals-CI: 5.57-275.84). Proportion meta-analysis indicated that complete resolution of symptoms is achieved in 80.5% of patients (95% CI: 59.3-92.1), while the proportion of participants necessitating intensive care unit admission is 7.0% (95% CI: 3.8-12.9). CONCLUSIONS: Myocarditis following mRNA Covid-19 vaccination is typically mild, following an uncomplicated clinical course with rapid improvement of symptoms. Future research is needed to define its exact incidence, clarify its pathophysiology and determine the optimal management plan depending on its severity. Protocol registration: dx.https://doi.org/10.17504/protocols.io.bxwtppen.
引用
- Bellos I, Karageorgiou V, Viskin D, et al. Myocarditis following mRNA Covid-19 vaccination: A pooled analysis. Vaccine. 2022. PMID: 35153093. doi:10.1016/j.vaccine.2022.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。